Kawartha Centre Redefining Healthy Aging

Peterborough, Ontario K9H2P4

1 studies enrolling now · 19 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Alzheimers Disease, Cognitive Dysfunction, Dementia, Early Alzheimer's Disease, Early Alzheimer´s Disease

Studies at this site

• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
• Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects — Stopped early
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease — Stopped early
• An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects — Completed
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease — Stopped early
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — Stopped early
• Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD) — Stopped early
• A Study of Gantenerumab in Participants With Mild Alzheimer Disease — Completed
• A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease — Completed
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) — Stopped early
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease — Stopped early
• A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab — Completed